SCHEMBL4557548

SCHEMBL4557548

O=C(Nc1cccc(F)c1F)C(=O)N1CCNCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.46
HRH4 Q9H3N8 1/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TP53 P04637 1/20 0.43
ABCC1 P33527 1/20 0.42
POLB P06746 1/20 0.41
CXCR2 P25025 1/20 0.39
CASP3 P42574 1/20 0.39
HPGD P15428 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
RAB9A P51151 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
TAS1R2 Q8TE23 1/20 0.38
AKT1 P31749 1/20 0.38
PIM1 P11309 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4559135 0.89 SMN1; SMN2 (0.51) SMN1; SMN2KMT2AALDH1A1L3MBTL1ABCC1
SCHEMBL4559727 0.78 SMN1; SMN2 (0.52) SMN1; SMN2KMT2AALDH1A1L3MBTL1TP53
SCHEMBL4559855 0.78 POLB (0.53) SMN1; SMN2HRH4KMT2AALDH1A1L3MBTL1
SCHEMBL4558440 0.77 NPC1 (0.57) SMN1; SMN2KMT2AALDH1A1L3MBTL1ABCC1
SCHEMBL4559701 0.75 ABCC1 (0.54) SMN1; SMN2KMT2AALDH1A1L3MBTL1ABCC1
SCHEMBL4558906 0.75 CCNC (0.52) SMN1; SMN2KMT2AALDH1A1L3MBTL1ABCC1
SCHEMBL4559529 0.74 KMT2A (0.78) SMN1; SMN2KMT2AALDH1A1L3MBTL1POLB
SCHEMBL4559491 0.74 TAS1R3 (0.50) SMN1; SMN2KMT2AALDH1A1L3MBTL1ABCC1
SCHEMBL4559520 0.74 L3MBTL1 (0.61) SMN1; SMN2KMT2AALDH1A1L3MBTL1HPGD
SCHEMBL669694 0.74 POLB (0.60) SMN1; SMN2KMT2AL3MBTL1ABCC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501407-B2 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2009-03-10 US disclosed
US-6916804-B2 Pyrimidine A2b selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2005-07-12 US disclosed
US-20050119271-A1 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119271-A1 Pyrimidine A2B selective antagonist compounds, their synthesis and use ADORA2B, ADORA2A, ADORA3 SMN1; SMN2 2019/4885HRH4 39/4885KMT2A 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.